Nature

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

The structural basis for imatinib resistance in chronic myeloid leukaemia (CML) involves the emergence of imatinib-resistant BCR-ABL point mutations; mutations are usually those that impair drug ...
Nature

Cleavage of BCR–ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR–ABL leukemic cells

In this study, we designed DNAzymes that specifically target and cleave the junction sequence and/or the site of point mutation conferring T315I drug resistance in BCR–ABL mRNA. The designed DNAzymes ...